Customers tell us they want peace of mind so that if a consumer has their beverage across multiple day parts, they will have a large margin before hitting tolerance levels. Why beverage brands need to brace themselves The thirst for GLP-1 medication only looks set to increase among consumers with the launch of unfussy, non-injectable formats A pill version of the appetite-suppressing drug, Wegovy, was unveiled by pharma giant Novo Nordisk in January Eli Lilly & Co is preparing to debut its own oral version, Orforglipron, post-FDA approval later this year The total GLP-1 pill market is forecast to leap from $3.2bn in 2025 to 34.3 bn in 2031, a CAGR of 48.4% (GlobalData) (Source GlobalData) GLP-1 drink NPD outside the box Although, its not just traditional food and beverage companies developing tailored NPD
PRCAUTIONS D'EMPLOI Ne doit pas se substituer une alimentation varie et quilibre et un mode de vie sain
Some patients actually tolerate tirzepatide better because the GIP pathway appears to buffer the GI response
Weeks 1 through 4: the quiet surprise Most researchers describe the first month as a revelation
How is PlexusDx tirzepatide priced
Subcutaneous injection deposits the peptide into the fatty tissue layer just beneath the skin
